Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $31.11 in the prior trading day, Twist Bioscience Corp (NASDAQ: TWST) closed at $31.7, up 1.90%. In other words, the price has increased by $1.90 from its previous closing price. On the day, 1.07 million shares were traded. TWST stock price reached its highest trading level at $31.785 during the session, while it also had its lowest trading level at $30.5825.
Ratios:
Our goal is to gain a better understanding of TWST by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 3.64. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In the most recent recommendation for this company, Stephens on November 04, 2025, initiated with a Overweight rating and assigned the stock a target price of $41.
On December 13, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $60.
On June 04, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $53.Guggenheim initiated its Buy rating on June 04, 2024, with a $53 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 21 ’25 when Cho Dennis sold 757 shares for $26.50 per share. The transaction valued at 20,063 led to the insider holds 145,402 shares of the business.
Finn Patrick John sold 1,776 shares of TWST for $47,070 on Nov 21 ’25. The President and COO now owns 332,883 shares after completing the transaction at $26.50 per share. On Nov 21 ’25, another insider, Green Paula, who serves as the SVP of Human Resources of the company, sold 598 shares for $26.50 each. As a result, the insider received 15,849 and left with 167,789 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 1938392448 and an Enterprise Value of 1796530432. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.15 while its Price-to-Book (P/B) ratio in mrq is 4.06. Its current Enterprise Value per Revenue stands at 4.771 whereas that against EBITDA is -15.717.
Stock Price History:
The Beta on a monthly basis for TWST is 2.24, which has changed by -0.35542905 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $55.33, while it has fallen to a 52-week low of $23.30. The 50-Day Moving Average of the stock is 5.29%, while the 200-Day Moving Average is calculated to be -5.57%.
Shares Statistics:
The stock has traded on average 1.78M shares per day over the past 3-months and 2414930 shares per day over the last 10 days, according to various share statistics. A total of 60.63M shares are outstanding, with a floating share count of 57.92M. Insiders hold about 5.28% of the company’s shares, while institutions hold 116.83% stake in the company. Shares short for TWST as of 1763078400 were 10898965 with a Short Ratio of 6.14, compared to 1760486400 on 10860765. Therefore, it implies a Short% of Shares Outstanding of 10898965 and a Short% of Float of 20.080000000000002.
Earnings Estimates
The stock of Twist Bioscience Corp (TWST) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.47 and low estimates of -$0.47.
Analysts are recommending an EPS of between -$1.76 and -$1.76 for the fiscal current year, implying an average EPS of -$1.76. EPS for the following year is -$1.08, with 8.0 analysts recommending between -$0.64 and -$1.54.
Revenue Estimates
6 analysts predict $100.33M in revenue for. The current quarter. It ranges from a high estimate of $101M to a low estimate of $100M. As of. The current estimate, Twist Bioscience Corp’s year-ago sales were $88.71MFor the next quarter, 6 analysts are estimating revenue of $105.08M. There is a high estimate of $109.1M for the next quarter, whereas the lowest estimate is $103.85M.
A total of 7 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $432.9M, while the lowest revenue estimate was $429.4M, resulting in an average revenue estimate of $430.84M. In the same quarter a year ago, actual revenue was $376.57MBased on 6 analysts’ estimates, the company’s revenue will be $497.01M in the next fiscal year. The high estimate is $503.8M and the low estimate is $485.63M.
